How Low Should You Go? Understanding the Safety and Effectiveness of Extremely Low LDL Cholesterol Levels

Table of Contents

• Key Points
• Background: Why LDL Cholesterol Matters
• How LDL Causes Heart Disease
• Current Treatments for High LDL
• The History of Very Low LDL Levels
• What Is Considered Low and Extremely Low LDL?
• Why Doctors Are Debating Extremely Low LDL
• What Research Shows About Safety and Benefits
• Future Directions and Ongoing Research
• Clinical Implications: What This Means for Patients
• Limitations of the Research
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• An LDL below 50 mg/dL is low; below 20 mg/dL is extremely low. PCSK9 inhibitors can lower LDL to as low as 15 mg/dL.
• Most studies show extremely low LDL is safe and reduces cardiovascular risk, but some trials reported more diabetes, liver problems, and insomnia when LDL dropped below 30 mg/dL.
• In the FOURIER trial, evolocumab lowered LDL from 92 to 30 mg/dL and significantly reduced major cardiovascular events.
• PCSK9 inhibitors can cause injection site reactions, flu-like symptoms, and rare allergic reactions; some patients develop antibodies that reduce effectiveness.
• For high-risk patients, aggressive LDL lowering may be life-saving, but the decision should be personalized with your doctor.

Background: Why LDL Cholesterol Matters

Heart disease is a leading cause of death in the United States, killing almost 400,000 people every year. High levels of LDL cholesterol (low-density lipoprotein, often called "bad" cholesterol) are strongly linked to coronary artery disease (CAD, narrowing of the heart's blood vessels). About 73.5 million adults in the USA have elevated LDL cholesterol.

Doctors have long known that the risk of cardiovascular disease (heart attacks and strokes) rises in a straight line with LDL levels. This means that even a small increase in LDL raises risk, and a small decrease lowers it. Current guidelines recommend treating patients to an LDL target of 70 mg/dL (milligrams per deciliter). However, even when patients reach this goal with high-intensity statin therapy (powerful cholesterol-lowering drugs), they still have leftover risk of heart problems.

This leftover risk is called "residual risk." Targeting other cholesterol types, like HDL (good cholesterol) and triglycerides (fats in the blood), has failed to reduce this risk. But new drugs called PCSK9 inhibitors can lower LDL far below current targets—down to as low as 15 mg/dL. This has brought back an old question: How low is low enough to minimize heart risk?

To answer this, researchers searched medical databases (PubMed, Embase, Scopus, and Google Scholar) and reviewed all relevant studies. This article summarizes what they found about the safety and effectiveness of lowering LDL below current goals.

How LDL Causes Heart Disease

LDL cholesterol is the single most important marker of atherosclerosis (hardening and narrowing of the arteries). Atherosclerosis happens when LDL particles damage the inner lining of arteries. This damage triggers inflammation and allows fatty streaks to form.

Over time, these streaks grow into plaques—stiff deposits made of cholesterol, dead cells, and calcium. Plaques can narrow arteries and block blood flow. If a plaque ruptures, it can cause a blood clot that leads to a heart attack or stroke.

The process is complex. LDL causes endothelial damage (injury to blood vessel walls). This attracts white blood cells, which turn into foam cells. Smooth muscle cells also migrate into the plaque. The result is a growing plaque that can eventually block the artery.

Atherosclerosis can be prevented by lifestyle changes and by controlling risk factors like high LDL. That is why lowering LDL is a top priority for heart health.

Current Treatments for High LDL

Several types of drugs lower LDL cholesterol. Each works differently and has its own benefits and side effects.

• Statins: These drugs block an enzyme called HMG-CoA reductase, which is needed to make cholesterol. Statins lower LDL and triglycerides, and slightly raise HDL. They are the standard treatment for high cholesterol. Side effects include liver damage, muscle pain, and a small increased risk of type 2 diabetes. However, the benefits outweigh the risks for most people. Statins also reduce inflammation.
• Ezetimibe: This drug prevents the absorption of bile acid in the small intestine. It lowers LDL, slightly raises HDL, and slightly lowers triglycerides. Side effects include muscle pain and abdominal pain.
• PCSK9 inhibitors: These are monoclonal antibodies (man-made immune proteins) called alirocumab and evolocumab. They work by blocking a protein called PCSK9, which normally destroys LDL receptors in the liver. By blocking PCSK9, these drugs allow more LDL receptors to remain, which clears more LDL from the blood. Side effects include nasopharyngitis (stuffy nose), injection site reactions, flu-like symptoms, and muscle soreness.
• Other drugs: Fibrates, bile acid binding resins, and niacin are also used to lower LDL, but they are less commonly prescribed today.

The History of Very Low LDL Levels

Some people are born with naturally low LDL levels. For example, individuals with hypobetalipoproteinemia (a genetic condition) or a PCSK9 mutation have inherited protection from coronary artery disease. People with a complete absence of PCSK9 have LDL levels around 15 mg/dL and suffer no ill effects.

Our ancestors, who lived as hunter-gatherers about 10,000 years ago, had average cholesterol levels of 50–75 mg/dL. They ate mostly nuts, fruits, vegetables, and wild animal meat. They were free from atherosclerosis. After the agricultural revolution, our diets changed dramatically to include processed foods, refined sugars, and carbohydrates. In only 500 generations, average cholesterol rose to 220–230 mg/dL. Our genes have not adapted to this high-cholesterol diet.

Interestingly, South Asian people are more prone to CAD even when their LDL is within target. This "South Asian paradox" suggests that further lowering LDL might help reduce atherosclerosis in these individuals.

What about the brain? The brain contains 25% of the body's cholesterol, but it makes its own cholesterol and does not rely on blood cholesterol. The blood-brain barrier prevents circulating cholesterol from entering the brain. We are born with LDL levels of 30–40 mg/dL, when the brain is developing rapidly. This suggests that low LDL is safe for the brain. A study by Ray et al. found that reducing LDL to levels seen in newborns is safe and reduces the risk of angina, heart attack, stroke, and death.

What Is Considered Low and Extremely Low LDL?

An LDL level below 50 mg/dL is considered low. A level below 20 mg/dL is considered extremely low. Intensive lipid-lowering treatment has been shown to halt the progression of atherosclerosis and even shrink plaques.

Several trials support this. The REVERSAL trial, the ASTEROID trial, and the SATURN trial all found that aggressive LDL lowering regresses plaque volume. An LDL level below 2.5 mmol/L (about 97 mg/dL) can cause plaques to shrink. The GLAGOV trial found that patients who received evolocumab on top of statins had plaque regression in 64.3% of cases versus 47.3% with placebo after 76 weeks. A retrospective analysis also showed that coronary calcium scores (a measure of plaque) were reduced with aggressive LDL lowering.

But does very low LDL cause harm? Some earlier trials reported increased risks of hemorrhagic stroke (bleeding in the brain), dementia, depression, blood in urine, and cancer. However, the Dallas Heart Study followed 12,887 people for 15 years. The Dallas Heart Study found that a PCSK9 mutation causing very low LDL was linked to a much lower risk of CAD. The reduction was 88% in black participants and 47% in white participants. There was no increase in hemorrhagic stroke or cancer. People with complete PCSK9 deficiency have LDL around 15 mg/dL and no reported adverse events.

Why Doctors Are Debating Extremely Low LDL

Most statin trials show an average 31% relative risk reduction in cardiovascular events. This means that 69% of the risk still remains. Despite widespread statin use, heart disease and strokes cause 25% of all deaths worldwide. There is clearly a need to address this residual risk.

A large meta-analysis by the Cholesterol Treatment Trialists (CTT) found that for every 1 mmol/L (about 39 mg/dL) reduction in LDL cholesterol, the risk of major cardiovascular events drops by 20–25%. Total mortality drops by 12%. The PROVE IT-TIMI study found that even when LDL was reduced to 62 mg/dL, there was still a 22.4% residual risk of cardiovascular events.

Why do statins leave residual risk? Statins not only lower LDL but also raise PCSK9 levels by 25–35% on average. This counteracts some of the benefit. PCSK9 inhibitors block this effect. A pooled analysis of 14 trials by Robinson et al. showed that alirocumab was safe and effective at lowering LDL even below 15 mg/dL. This has intensified the debate about how low LDL should go.

What Research Shows About Safety and Benefits

Many trials have tested the effects of lowering LDL below recommended levels. The results are largely encouraging. Here is a summary of the key findings.

• TNT Trial: Compared very low LDL-C levels with higher levels. Lower LDL led to a 22% decrease in combined cardiovascular events (coronary artery disease, nonfatal heart attack, resuscitated cardiac arrest) and a 20% reduction in cardiac deaths. Side effects like muscle pain, hemorrhagic stroke, and cancer death were not increased.
• IMPROVE-IT: 18,144 patients with acute coronary syndrome were randomly assigned to simvastatin 40 mg plus ezetimibe 10 mg, or simvastatin 40 mg plus placebo. After 7 years, the combination group had a significantly lower rate of cardiovascular death, major coronary events, or nonfatal stroke (32.7% vs 34.7%). This benefit was seen even in patients whose baseline LDL was already well below the target.
• 2007 Study: Patients with LDL-C below 60 mg/dL who also had diabetes or ischemic heart disease were given statins. After an average follow-up of 2.0 years (plus or minus 1.4 years), statins improved survival in those taking them at baseline. The hazard ratio was 0.58; the 95% confidence interval was 0.38 to 0.88. Statins also improved survival in those with LDL-C below 40 mg/dL. There was no increased risk of liver enzyme elevation, cancer, or rhabdomyolysis (muscle breakdown).
• JUPITER Trial: Patients treated with rosuvastatin who achieved LDL-C below 50 mg/dL had a 65% reduction in major cardiovascular events, compared to 44% for the rest of the group. All-cause mortality dropped by 46% in the low-LDL group versus 20% in the others. However, patients with LDL-C below 30 mg/dL had a higher rate of adverse events, including diabetes, liver disorders, and insomnia.
• SPARCL Study: In patients with stroke or transient ischemic attack (TIA, a mini-stroke), atorvastatin 80 mg reduced the chance of stroke but increased the incidence of hemorrhagic stroke (bleeding in the brain).
• Another Statin Study: In patients with a history of heart attack, 80 mg simvastatin vs 20 mg simvastatin showed no difference in hemorrhagic stroke after an average follow-up of 6.7 years. However, myopathy (muscle damage) was more common with the 80 mg dose.
• Robinson et al. (Alirocumab): LDL-C levels as low as 15 mg/dL were achieved with no adverse neurocognitive events. There was a non-significant increase in cataract incidence in those achieving LDL-C below 25 mg/dL.
• Sabatine et al.: No significant increase in adverse reactions with very low LDL-C.
• Prostate Cancer Prevention Trial: Low cholesterol was associated with a reduced risk of high-grade prostate cancer.
• Quebec Study: A retrospective study in Quebec, Canada, found that high-dose statin use might be associated with a significant reduction in cancer incidence.
• PROVE IT-TIMI 22 Substudy: Comparing 80 mg atorvastatin with 40 mg pravastatin, achieving LDL-C below the expected level (80 to 100 mg/dL) was not associated with increased adverse events.
• Boekholdt et al. Meta-analysis: Found an increased risk of hemorrhagic stroke in people with very low LDL compared to moderately low LDL. However, the absolute number of events was low, and the statistical power was insufficient to draw a definite conclusion. The authors believed that the significantly lower risk of other cerebrovascular events outweighed the potential for hemorrhagic stroke.
• Phase 3 Study of Evolocumab: Showed no increase in adverse events despite a median LDL level of 26–36 mg/dL over 12 weeks.
• FOURIER Trial: Evolocumab reduced LDL from a baseline of 92 mg/dL to 30 mg/dL. There was a significant decrease in major cardiovascular events without a major rise in adverse events. Lowering LDL to 43 mg/dL reduced the risk of cardiovascular death, heart attack, and stroke by 17%. Further lowering to 22 mg/dL reduced the risk by 20%. Each unit reduction in LDL produced consistent clinical improvement.
• ODYSSEY Trials (Post Hoc Analysis): Compared alirocumab with control. Low LDL-C was associated with a lower incidence of major adverse cardiovascular events and no significant increase in treatment-emergent adverse reactions.
• IMPROVE-IT Prespecified Safety Analysis: Of 15,281 patients, 971 achieved LDL below 30 mg/dL. These patients had no increased adverse events over six years of follow-up.

In summary, most studies show that extremely low LDL is safe and reduces cardiovascular risk. Some trials reported higher rates of diabetes, liver problems, and insomnia when LDL dropped below 30 mg/dL. Hemorrhagic stroke risk was slightly increased in some analyses, but the absolute risk was low and outweighed by the reduction in other strokes and heart attacks.

Future Directions and Ongoing Research

Despite the promising results, many questions remain. The long-term effects of prolonged very low LDL levels are still unknown. There is often a time lag between lowering LDL and seeing clinical benefits, which complicates the picture.

PCSK9 inhibitors are effective but expensive. Their cost-effectiveness is questionable. They can also cause immune reactions, from mild injection site reactions to rare anaphylaxis (severe allergic reaction). Some patients develop antibodies against the drug, which can reduce its effectiveness. In the SPIRE trial, 15–20% of patients developed antibodies against bococizumab (a similar drug), and neutralizing antidrug antibodies were seen in 1.3% of patients on alirocumab. Poor adherence due to multiple injections is another issue.

A new approach uses small interfering RNA (siRNA) to target PCSK9. Inclisiran is a drug that uses RNA interference to block PCSK9 production. In the ORION-1 trial, inclisiran reduced LDL by an average of 51% with just two doses over 9 months. This ease of use could improve adherence. However, its impact on cardiovascular outcomes is not yet known; the ORION-4 trial is studying this.

Peptide-based anti-PCSK9 vaccines are being tested in mice and may control LDL for longer periods. Several ongoing studies aim to clarify the safety of low LDL. The ODYSSEY OUTCOMES trial is randomizing 18,600 patients who have had a heart attack to alirocumab or placebo. The results will provide more definitive answers.

Clinical Implications: What This Means for Patients

The evidence suggests that for patients at high risk of heart disease, lowering LDL to very low levels is safe and reduces the chance of heart attacks and strokes. This is especially true for those who cannot reach target LDL with statins alone or who cannot tolerate statins.

New drugs like PCSK9 inhibitors offer a powerful option. They can be used alone or with statins. For patients with existing heart disease, diabetes, or inherited high cholesterol, aggressive LDL lowering may be life-saving.

However, not everyone needs extremely low LDL. The decision should be personalized. Patients should discuss their LDL target with their doctor, considering their overall risk, other health conditions, and medication tolerance.

Limitations of the Research

Many of the studies reviewed were post hoc analyses or meta-analyses, which can have weaknesses. Long-term safety data beyond a few years are limited. Some trials did show increased risks—such as diabetes, liver disorders, and hemorrhagic stroke—when LDL dropped very low, though these events were rare.

Statistical power was insufficient in some analyses to draw firm conclusions about rare side effects. Cost and adherence issues with injectable drugs may limit their real-world use. Also, the time lag between LDL lowering and clinical benefit means that short-term studies may underestimate the full effect.

Recommendations for Patients

Based on this review, here is what patients can do:

1. Know your LDL number. Ask your doctor for your lipid panel results and understand your target.
2. Follow a heart-healthy lifestyle. Eat a diet rich in fruits, vegetables, nuts, and whole grains. Limit processed foods, refined sugars, and saturated fats.
3. Take medications as prescribed. Statins and other LDL-lowering drugs are proven to reduce heart attacks and strokes. If you have side effects, talk to your doctor—do not stop suddenly.
4. Discuss newer treatments. If your LDL remains high despite statins, ask about PCSK9 inhibitors, ezetimibe, or other options.
5. Monitor for side effects. Report any muscle pain, weakness, dark urine, or unusual bleeding to your doctor.
6. Stay informed. New research is ongoing. Ask your doctor about the latest guidelines and clinical trials.

Frequently Asked Questions

What is considered extremely low LDL cholesterol?

An LDL level below 50 mg/dL is considered low, and a level below 20 mg/dL is considered extremely low. New drugs called PCSK9 inhibitors can lower LDL to as low as 15 mg/dL. People born with a complete absence of PCSK9 naturally have LDL around 15 mg/dL and suffer no ill effects.

Is extremely low LDL cholesterol safe?

Most studies show that extremely low LDL is safe and reduces cardiovascular risk. In a pooled analysis of 14 trials, alirocumab was safe and effective even below 15 mg/dL. However, some trials reported higher rates of diabetes, liver problems, and insomnia when LDL dropped below 30 mg/dL, and hemorrhagic stroke risk was slightly increased in some analyses.

Does lowering LDL very low prevent heart attacks and strokes?

Yes, aggressive LDL lowering reduces cardiovascular events. In the FOURIER trial, evolocumab lowered LDL from 92 to 30 mg/dL and significantly decreased major cardiovascular events. Lowering LDL to 43 mg/dL reduced the risk of cardiovascular death, heart attack, and stroke by 17%, and further lowering to 22 mg/dL reduced it by 20%.

What are PCSK9 inhibitors and how do they work?

PCSK9 inhibitors are monoclonal antibodies called alirocumab and evolocumab. They block a protein called PCSK9, which normally destroys LDL receptors in the liver. By blocking PCSK9, these drugs allow more LDL receptors to remain, which clears more LDL from the blood. They can be used alone or with statins.

What side effects can PCSK9 inhibitors cause?

Side effects include nasopharyngitis (stuffy nose), injection site reactions, flu-like symptoms, and muscle soreness. They can also cause immune reactions, from mild injection site reactions to rare anaphylaxis. Some patients develop antibodies against the drug, which can reduce its effectiveness. In the SPIRE trial, 15–20% of patients developed antibodies against bococizumab.

Who might benefit from extremely low LDL treatment?

For patients at high risk of heart disease, lowering LDL to very low levels is safe and reduces the chance of heart attacks and strokes. This is especially true for those who cannot reach target LDL with statins alone or who cannot tolerate statins. For patients with existing heart disease, diabetes, or inherited high cholesterol, aggressive LDL lowering may be life-saving.

What should I do if I have high LDL cholesterol?

Know your LDL number and ask your doctor for your lipid panel results and target. Follow a heart-healthy lifestyle rich in fruits, vegetables, nuts, and whole grains, and limit processed foods, refined sugars, and saturated fats. Take medications as prescribed. If you have side effects, talk to your doctor—do not stop suddenly. Discuss newer treatments if your LDL remains high.

If my LDL is already below 70 mg/dL on a statin but I still have heart disease risk, when should I get a second opinion about lowering it further?

When LDL is at goal but residual risk remains, or when very low targets below 50 mg/dL are proposed, a second opinion can help weigh the evidence. Trials show aggressive lowering regresses plaque and reduces events. Yet some data link levels below 30 mg/dL to diabetes, liver disorders, insomnia, and slightly more hemorrhagic stroke. The absolute risk is low. A second opinion can clarify whether PCSK9 inhibitors, ezetimibe, or continued statins fit your risk profile, tolerance, and cost considerations. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Safety-and-Efficacy-of-Extremely-Low-LDL-Cholesterol

Authors: Dhrubajyoti Bandyopadhyay, Arshna Qureshi, Sudeshna Ghosh, Kumar Ashish, Lyndsey R. Heise, Adrija Hajra, and Raktim K. Ghosh

Publication details: Hindawi Journal of Lipids, Volume 2018, Article ID 8598054, 8 pages. doi: 10.1155/2018/8598054. Received 19 November 2017; Accepted 14 March 2018; Published 23 April 2018.

Note: This patient-friendly article is based on peer-reviewed research. It is for informational purposes only and does not replace advice from your healthcare provider.